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Ehrlichiosiscomprisesagroupofemergingtick-borneinfectiousdiseasescausedbyobligate
intracellularGram-negativebacteria that infect leukocytes. Infectionscausedbymembersof
the genus Ehrlichia have been described in animals and humans, but to date there are no
convincingreportsofthepresenceofothertypesofhumanehrlichiosisdifferentfromhuman
granulocytic ehrlichiosis (HGE) inEurope. TheEuropeanvector is the sameas that of Lyme
borreliosis, thehardtick Ixodesricinus, andHGEhasasimilarepidemiologyto thatofBorrelia
burgdorferi infection.AcrossEurope, I. ricinus is infected toavariableextent (0.4–66.7%)with
the causative agent Ehrlichia (Anaplasma) phagocytophila genogroup, and since its ﬁrst
description in Slovenia in 1997, details of 15 patients have been published. Diagnosis
requires careful consideration of all circumstances and symptoms (history of tick bite
andthepresenceofaﬂu-likesyndromewithvariabledegreesofanemia, thrombocytopenia,
and leukopenia, andelevated liver enzymes). Somedifferences canbe seenbetweenUSand
EuropeanHGEpatients.EuropeanHGEcaseshavea less severe course, and thepresenceof
morulae is uncommon. In Europe, veriﬁcation of HGE has been based on PCR and
immunoﬂuorescence antibody tests, because no isolation from humans has been reported.
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Tick-borne diseases (TBDs) represent a public-
health problem of growing importance. The emer-
gence and recognition of an increasing number of
new TBDs in recent years highlights the signiﬁ-
cance of this zoonosis [1,2].
Ehrlichiosis comprises a group of emerging
infectious TBDs caused by obligate intracellular
Gram-negative bacteria that infect leukocytes.
Someof these have beendemonstrated to behuman
pathogens [3,4]. The species mainly implicated in
human diseases are shown in Table 1.
The causative agent of human granulocytic ehr-
lichiosis (HGE) still has no namebut is closely relat-
ed to Anaplasma phagocytophila (formerly Ehrlichia
phagocytophila) and Ehrlichia equi (E. phagocytophila
genogroup) [3]. To date, there are no convincing re-
ports of the presence of human ehrlichiosis diffe-
rentfromHGEinEurope[1,5–7]. Itsvector inEurope
isthetickIxodesricinus [1,4,5,8–20].Inthisupdate,we
reviewHGE in Europe, andwewillmake reference
to US series when there are differences. Obviously,
the increase in travel between continents increases
the risk of other types of human ehrlichiosis.
The ﬁrst description of HGE was communicated
in the USA in 1994 [3,21], and since then about 600
cases have been reported [22]. In Europe, we
have had knowledge of animal infections with
ehrlichias of the E. phagocytophila genogroup have
been acknowledged since before the middle of the
last century [5], and the ﬁrst (serologic) evidence of
the presence of an HGE agent in humans was
described in Switzerland in 1995 [23]. The ﬁrst
conﬁrmed case of this infection was described in
Slovenia in 1997 [24]. Since then, HGE infection
has been described in Slovenia [6,7,24], TheNether-
lands [25], Spain [26], Sweden [27–29],Norway [29],
Croatia [30], and Poland [31]. Tables 2 and 3 show
the epidemiological, clinical and microbiological
characteristics of the accessible reported European
cases.
EPIDEMIOLOGY
The natural history of HGE is still being deﬁned,
but it is possible that the HGE agent is maintained
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in nature in a tick–ruminant–rodent cycle.
Humans are involved only as accidental ‘dead-
end’ hosts. Most patients report exposure to ticks
or tick bite between 7 and 30days before the onset
of the disease [6,7,24,26,27,31,32].
The HGE agent is transmitted by I. ricinus.
Small mammals, in particular Apodemus sylvaticus
(woodmouse),Apodemus ﬂavicollis (yellow-necked
mouse), Sorex araneus (common shrew) and, espe-
cially, Clethrinomys glareolus (bank vole) have been
implicated as reservoirs of granulocytic ehrlichiae
in Europe [5,14]. HGE agents have also been
detected in mammals such as sheep, lambs, dogs,
goats, and horses [5,15,33,34]. As in other TBDs
(e.g. Lyme borreliosis (LB)), birds may play a role
in the epidemiology and dissemination of HGE
[35]. In birds, Ehrlichia DNA was detected in none
of the larvae, 8% of the nymphs and none of the
adult ticks, suggesting that birds are incompetent
reservoirs but act as carriers [35].
Depending on the geographic location, the pre-
valence of the E. phagocytophila genogroup in I.
ricinus ticks ranges from 0.4% to 66.7% [8–12,
14–20,36] (Table 4). Members of the E. phagocyto-
phila genogroup have been found more frequently
in adult ticks than in nymphs [9,14,15,18,36],
although other workers have reported a higher
percentage of infection in nymphs [12,16]. This
variability could be due to geographic or environ-
mental differences, inﬂuencing intermediate host
species or reservoirs.
Table 1 Main ehrlichiosis agents implicated in human
pathology
Ehrlichia spp. Target cell
E. canis genogroup
E. canis Monocytes
E. chaffeensis Monocytes
E. ewingii Granulocytes
E. phagocytophila genogroup
Human granulocytic ehrlichiosis agent Granulocytes
E. sennetsu genogroup
E. sennetsu Monocytes
Table 2 Epidemiological and clinical characteristics of the European cases available
Country Month Age/Sex Tick-bite/Days Clinical findings and physical examination
Slovenia [6,24] June 70/F Yes/12 Fever (40 8C), headache, nausea, vomiting,
malaise, myalgias, arthralgias, conjunctivitis,
lymphadenopathy
Slovenia [6] June 59/F Yes/21 Fever (41 8C), chills, headache, vertigo,
nausea, malaise, myalgias, arthralgia
Slovenia [6] July 43/M Yes/7 Fever (40 8C), chills, headache, vertigo,
nausea, malaise, myalgias, arthralgia, cough
Slovenia [6] August 55/F Yes/30 Fever (39.3 8C), headache, vertigo, nausea,
malaise, myalgias, arthralgia, vomiting
Slovenia [32] August 36/M Yes/15 Fever (39.2 8C), malaise, headache, chills,
lymphadenopathy, hepatosplenomegaly
Slovenia [7] February 11/F Yes/9 Fever (38 8C), fatigue, headache, nausea,
abdominal pain, conjunctivitis,
erythematous throat
The Netherlands [25] September 58/M No Fever (39.8 8C), chills, diarrhea
Spain [26] August 19/M Yes/15 Fever (39 8C), malaise, headache,
myalgias, abdominal pain
Sweden [27] August 5/F NA Fever, headache, facial palsy
Sweden [27] October 41/M NA Fever, headache, dyspnea, cough,
conjunctivitis, rash
Sweden [27] August 32/F Yes/> 30 Fever, chills, headache, stiff neck
Sweden [28] October 41/M No Fever (39 8C), myalgias, headache, cough,
dyspnea, conjunctivitis, rash
Poland [31] June 40/F No Fever (39 8C), malaise, headache, nausea,
hepatomegaly
Poland [31] July 41/M Yes/7 Fever (40 8C), headache, vertigo, nausea,
weakness, hepatomegaly
Poland [31] July 22/M Yes/7 Fever (39.2 8C), headache, nausea, vomiting,
abdominal pain, diarrhea, splenomegaly
NA, not available.
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The epidemiology of HGE is very similar to that
of LB, and tick bite is the main risk factor for HGE;
however patients with no recognized tick bite,
such as butchers who cut deer carcasses, and
hunters in contact with infected deer blood, also
constitute a risk group in the USA [37–39]. Trans-
fusion transmission of ehrlichiosis is biologically
plausible [40,41], and perinatal transmission of the
agent of HGE to human infants has been docu-
mented outside of Europe and may have resulted
from transplacental spread [42].
In Europe, human seroepidemiologic surveys of
the HGE agent have found prevalences of antibo-
dies of 0–2.9% in blood donors and 1.5–21% in tick-
exposed individuals (Table 4) [5,16,23,27,43–55].
The majority of cases in which the authors com-
ment on seasonality (Table 2) occurred between
June and August (73%), a period of higher activity
of the vector in these areas. In 67% of patients,
there was a history of tick bite seven to 30 days
before the onset of the disease [6,7,24,26,31,32]. The
median age was 38 years (range 5–70 years); nearly
20% of patients were less than 20 years old, and
53% of cases occurred in men. Similar ﬁndings
have been reported from the USA [22,56,5760]. In
Table 5, we show some differences between two
large US series and between these and the cases
reported in Europe.
CLINICAL MANIFESTATIONS
After infection,very fewindividualsdevelopsymp-
toms, and it seems thatHGEcases inEuropeare less
severe than those in North America. Clinically,
HumanMonocytic Ehrlichiosis (HGE) can be indis-
tinguishable fromHME. Inmost patients, ehrlichio-
sis consists of ﬂu-like symptoms (fever, myalgias,
arthralgias, and headache). Physical examination
reveals a few abnormalities, such as conjunctivitis
and lymphadenopathy [6,7,24,27,28,32].
In the USA, a rash occurs in approximately one-
third of patients with HME, but is less common in
patients with HGE (1–11%) [22,56,58]. In Europe,
only two patients with rash have been reported
[27,28]. Thus, a difference between tick-borne rick-
ettsiosis and LB is the absence of skin lesions in the
majority of cases in the former. Table 5 shows other
manifestations that can accompany the illness in a
low percentage of patients.
Pulmonary manifestations include dry cough,
pneumonia (clinical characteristics of atypical
pneumonia) [6], and the presence of pulmonaryT
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inﬁltrates [27,28]. Gastrointestinal manifestations
have also been described, and include nausea,
vomiting, diarrhea, and abdominal pain [6,7,24–
26,31]. Hepatomegaly, splenomegaly or both are
occasionally described [31,32].
Although patients can have symptoms and signs
that might suggest meningeal involvement (i.e.
fever, headache, and nausea) [27,31], no cases of
meningitis or pathologic cerebrospinal ﬂuid (CSF)
have been reported in Europe. In US patients, there
Country I. ricinus ticks Human
Bulgaria [43] 9.7%a
Denmark [47,54] 3.8% to 21%a
England [15] 1.4–9%
France [5,17] 1.25% 1.6%a to 17%b
Germany [46] 11.4%a to 14%c
Hungary [5] 12.5%c
Italy [10,48] 24.4% 1.5%b to 8.6%c
Norway [12,52] 6–11.5% 10.2%a
Scotland [8] 0.25–2%
Slovenia [19,44] 3.2% 15.4%d
Spain [9,16] 0–25% of adults;
0.4–66.7% of nymphs
0%d to 1.9%d to 2.3%a
Sweden [20,45,53] 6.6% 8.1%a to 11.5%b
Switzerland [14,18,23,36,49] 0.4–2.1% 7.4% to 17.1%c
UK [50,56] 1.5%c to 5%c to 7.5%a
Wales [11] 7%
aPatients with Lyme borreliosis or neuroborreliosis.
bPatients who live in I. ricinus-exposed areas.
cTick-exposed individuals (hunters, forestry workers, farm workers).
dHealthy individuals.
Table 4 European seroprevalence in
Ixodes ricinus ticks and human sera
Europe (n¼ 15)
[6,7,24–28,31,32]
New York State
(n¼ 18) [58]
Midwestern USA
(n¼ 41) [56]
Male sex 53% 61% 78%
Fever 100% 94% 100%
Malaise 47% NA 98%
Rigors, chills 27% 39% 98%
Myalgias 40% 61% 98%
Weakness 13% NA 17%
Arthralgias 27% 61% 27%
Sweats NA NA 98%
Headache 93% 78% 85%
Anorexia NA 6% 37%
Nausea 53% 6% 39%
Vomiting 20% NA 34%
Megalies 20% NA NA
Abdominal pain 20% NA NA
Diarrhea 13% 17% 10%
Cough 20% NA 29%
Pneumonia 13% NA 10%
Confusion NA NA 17%
Seizure NA NA 2%
Vertigo 33% NA 5%
Conjunctivitis 27% NA NA
Lymphadenopathy 13% NA NA
Rash 7% 11% 2%
Death 0% 0% 5%
Morulae 7% 25% 68%
NA, not available.
Table 5 Characteristics, signs, sym-
ptoms, outcome and presence of
morulae observed in different areas
of the USA and Europe
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is no clear evidence of such processes occurring
with the HGE agent [56], and when a lumbar punc-
ture is performed, this shows normal CSF [56,61],
in contrast to the case with HME [62].
Simultaneous human infections by the HGE
agent and other TBD agents, such as the LB
agent, babesiosis and tick-borne encephalitis virus,
are possible since I. ricinus is the common vector
[5,10–16,27,30,31,43,45–47,49,50,52–54].
COMPLICATIONS AND OUTCOME
In Europe, the clinical course of the patients is
favorable (Table 3). In US series, mortality has been
estimated to be 0–5% [21,39,56,58,59]. Most deaths
are associated with opportunistic infections due to
immunosuppression (ehrlichia-induced neutrope-
nia) or underlying disease [21,56,63]. In Europe, so
far, no death has been reported to be associated
with HGE.
In the USA, 8.7–56% of patients were hospita-
lized [38,56,58,60]. In European series, all but three
patients (80%) were admitted to hospital. Table 6
shows the complications of HGE infection. These
include a sepsis-like syndrome with disseminated
intravascularcoagulation[21],adultrespiratorydis-
tress syndrome [29,64], peripheral neuropathies
[65,66], uni- or bilateral facial palsy [27,67], vertigo
[6,31],pancarditis [63],pericardialeffusionandtam-
ponade [61], rhabdomyolysis [25], and severe op-
portunistic and nosocomial infections [21,56,63]. In
theUSA, there are nodata on the possibility that the
HGE agent can cause a chronic disease, and all but
two patients recovered successfully [65,66]. A case
ofreinfectionwiththeHGEagenthasbeendescribed
in the USA [68].
DIAGNOSIS
Diagnosis requires careful consideration of circum-
stances and symptoms. Laboratory tests typically
show leukopenia, thrombocytopenia, and raised
serum hepatic aminotransferase levels. Also, ery-
throcyte sedimentation rate and C-reactive protein
can be elevated [6,56,58,69]. The diagnosis of HGE
is easy when the patient remembers a tick bite and
presents with a ﬂu-like syndrome with the above
analytic ﬁndings in an area where LB is endemic.
Physicians should not exclude this illness on the
basis of normal analytic parameters [69]. If there is
a suspicion of HGE, blood samples must be eval-
uated with a manual differential leukocyte count,
which also permits screening for ehrlichial mor-
ulae (intracellular clumps of Ehrlichia) within the
neutrophils [69].
HGEmay be conﬁrmed by culture, examinations
ofperipheralbloodsmears(Wright,Giemsa-stained
smears), serology, or PCR on an acute-phase blood
sample. In Europe, veriﬁcation of HGE has been
based on PCR and the immunoﬂuorescence anti-
body test (IFA). No isolation from humans has
been reported.
The Centers for Disease Control (CDC) estab-
lished the case deﬁnition of HGE in 1997 [70], but
this is being revised. Ehrlichiosis is described as an
acute illness accompanied by headache, myalgias,
rigors and/or malaise for which one of three
laboratory criteria must be present: (1) seroconver-
sion (four-fold or greater rise in IFA assay); (2) a
positive PCR; or (3) the presence of morulae in
blood, bone marrow, or CSF leukocytes, and an
IFA antibody titer 64. Recently, a consensus
group of experts [71] has suggested that, because
a positive PCR result in the absence of either
serologic evidence or the isolation of ehrlichiae
could be false positive, the conﬁrmation of a case
would require both a positive PCR and detection
of morulae. To date, there is no deﬁnition
approved by consensus in Europe.
Culture
To date, no cultures of the HGE agent have been
performed inEurope. Therefore,wewill refer to the
USexperience, since thedeﬁnitiveevidenceof infec-
tion is isolation of the organism in culture (HL60
leukemia cells) [61]. Cultures show a rapid devel-
opment of cytopathic effects, and allow the direct
visualization of the organismwithin ﬁve to 12days
Table 6 Complications reported in Europe and the USA
Europe USA
Vertigo Vertigo
Facial palsy Facial palsy
Severe opportunistic
and nosocomial
infection
Severe opportunistic
and nosocomial
infection
Adult respiratory
distress syndrome
Adult respiratory
distress syndrome
Rhabdomyolysis Sepsis-like syndrome with DIC
Peripheral neuropathies
Plexopathy
Pancarditis
Pericardial effusion and tamponade
DIC, disseminated intravascular coagulation.
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after inoculation. Cultures are positive in 34.8% of
cases, independent of the incubation period or the
characteristics of the initial symptoms [60]. Fever
(>38 8C), leukopenia (<4500/mm3), lymphopenia
(<1500/mm3) and thrombocytopenia (<160 000/
mm3) occur signiﬁcantly more frequently in cul-
ture-positive cases [60]. Detection of morulae, and
PCR analysis positive for the HGE agents, are most
common in culture-positive cases [58,60].
Morulae
TheHGE agent infects the cytoplasm of circulating
leukocytes, causing intracellular clumps known as
morulae. Test for detection has a high speciﬁcity
but low sensitivity. The presence of morulae in
stained blood, bone marrow or CSF leukocytes is
evidence of the presence of ehrlichiae infection,
but not for speciﬁc species, and supports the diag-
nosis [21,56,58]. In US patients with HGE infection,
morulae are present in 25–68% of cases [56,58,60,
61]. In Europe, morulae have been detected in only
one patient [25]. The success in ﬁnding morulae
varies in accordance with the experience of the
microscopist and the duration of the illness [22].
Morulae are usually detected in blood smears only
during acute febrile episodes [56,58]. The presence
of morulae correlates with the age of the patient
(older than 50 years), and a positive PCR [58].
False-positive results could be due to the observa-
tion of toxic granulations or Dohle bodies.
Serology
Conﬁrmation by IFA is the most common diag-
nostic technique [72]. This is a sensitive tool for
laboratory conﬁrmation of HGE in acute-phase
and convalescent-phase serum samples [73]. The
IFA test for HGE can be performed employing the
USG3 isolate of the HGE agent grown inHL-60 cell
culture as antigen [72], or based on horse granu-
locytes infected with E. equi.
In Europe, serology was positive in 80% of the
cases. Of these, all but one had positive serology by
the ﬁrst month. In the USA, among patients with
conﬁrmed HGE (detection of morulae in blood
smears, conﬁrmation by PCR, blood culture, or a
combination of these), all but one (99.2%) tested at
the ﬁrst month were seropositive, 98.7% became
seropositive by sixmonths, while 7.3% remained
seropositive at 42months. Neither antibiotic ther-
apy initiated during the ﬁrst week of illness nor
pre-existing immunosuppressive conditions pre-
vented a serologic response [73].
Serology may give false-positive results [74].
Cross-reactivity between the HGE agent and
E. chaffeensis has been described in 30–53.8% of
patients with conﬁrmed or probable HGE [39,59].
To date, in Europe, there are no convincing reports
of the presence of types of human ehrlichiosis
different from that caused by the HGE agent
[1,5–7]. This could be due to cross-reactivity
between the HGE agent and other Ehrlichia spp.,
such as E. chaffeensis or E. ewingii [6,7].
Cross-reactivity to theHGEagent and other rick-
ettsial agents (Coxiella burnetii, Rickettsia rickettsii,
and Rickettsia typhi) has also been described [39,75].
At least in relation to other TBD-like LBs, the
presence of both Borrelia burgdorferi and HGE
agent antibodies at the same time may be ex-
plained by serologic cross-reaction, co-exposure,
or co-infection [13,27,31,42,46,47,76–79]. However,
Wormser et al. [80] proposed that active HGE
infection could be a cause of false-positive LB
serology results when ELISA and immunoblotting
were employed. Further observations suggest that,
for those patients with HGE, serodiagnosis is
insufﬁcient to establish the presence of co-infec-
tion with B. burgdorferi [81]. However, a mouse
model of infection with the HGE agent showed
that this infection did not induce B. burgdorferi
serologic cross-reactions [82].
PCR
Methods based on PCRgene ampliﬁcation could be
useful, sensitive and rapid for the detection and
identiﬁcation of tick-borne pathogens from blood,
ticks,andskinbiopsyspecimens[4,83,84].PCRwasa
useful diagnostic tool in 73% of European cases. In
fourcases (27%), serologywaspositivebutPCRwas
negative, so a negative PCR result does not exclude
the diagnosis [6,26,31,32,56,58,60].
Several PCR-based molecular assays are avail-
able for the detection of the E. phagocytophila gen-
ogroup, and different types of primer can be
employed (e.g. ge2, ge9f, ge10r) [4,6,31,53,83–85].
As with serology, the assay is not standardized.
DIFFERENTIAL DIAGNOSIS
In Europe, the differential diagnosis of TBD with
acute febrile illness includes a large list of infec-
tious processes (LB, HGE, babesiosis, tularemia,
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tick-borne encephalitis, Mediterranean spotted
fever, and Dermacentor-borne necrosis, erythema
and lymphadenopathy or tick-borne lymphadeno-
pathy). This list will depend on the geographic
location, season, and presence of the vector in the
area. Ehrlichiosis must be suspected in previously
healthy individuals who develop fever after out-
door activity, and in patients exposed to ticks who
develop fever, leukopenia, thrombocytopenia, or
elevated transaminases, or do not respond to treat-
ment with b-lactams or macrolides, especially in
an LB-endemic area [23,26,27,69,86].
TREATMENT
In European HE, the outcome is favorable. In some
cases, symptoms abate even without the use of
antibiotics [6,7,30,32]. In any case, empirical ther-
apy should be started without waiting for micro-
biological conﬁrmation.
Many antibiotics, including doxycycline, rifam-
pin, and ﬂuoroquinolones (such as ciproﬂoxacin,
oﬂoxacin, levoﬂoxacin, and trovaﬂoxacin), have
demonstrated signiﬁcant activity against the
HGE agent [87,88]. The HGE agent is resistant
to clindamycin, trimethoprim–sulfamethoxazole,
and imipenem–cilastatin, as well as to ampicillin,
amoxicillin, ceftriaxone, erythromycin, clarithro-
mycin, and azithromycin [87,88], although a favor-
able outcome has been reportedwith azithromycin
[6]. Chloramphenicol and gentamicin have weak
inhibitory activity against the HGE agent, and
should not be used [87].
The drug of choice is doxycycline (100mg twice
daily) for 7–10 days. In cases of intolerance to doxy-
cycline, rifampin and the quinolones are useful.
Rifampin can be reserved for pregnant women.
Symptoms resolve by 24–48 h after the start of
therapy [56,58]. In the absence of a response,
diagnoses other than HGE should be considered.
PREVENTION AND PROPHYLAXIS
General procedures used for preventing other
TBDs are recommended. Avoiding exposure to
ticks is the best method of prevention of ehrlichio-
sis and the other TBDs. As for other TBDs, using
insecticide sprays or repellents and wearing pro-
tective clothing are useful in reducing the risk of
tick attachment [1,4,89].
Because the HGE agent can be transmitted dur-
ing the ﬁrst hours of tick attachment, prompt
removal of the tick does not exclude the infection
[90]. We do not have any knowledge of the pre-
vention of HGE with chemoprophylaxis.
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ADDENDA
Since the review was written, new nomenclature
(Anaplasma phagocytophila) has been proposed; see
Dumler JS, Barbet AF, Bekker CP, Dasch GA,
Palmer GH, Ray SC, Rikihisa Y, Rurangirwa FR.
Reorganization of genera in the families Rickettsia-
ceae and Anaplasmataceae in the order Rickettsiales:
uniﬁcation of some species of Ehrlichia with Ana-
plasma, Cowdria with Ehrlichia, and Ehrlichia with
Neorickettsia, descriptions of six new species com-
binations and designation of Ehrlichia equi and
‘HGE agent’ as subjective synonyms of Ehrlichia
phagocytophila. Int J Syst Evol Microbiol 2001;51:
2145–2165.
Recently, a new granulocytic ehrlichiosis has
been described in Italy from Ixodes ricinus. This
new specie has been named Ehrlcihia walkerii in
honor to David H. Walker, see Brouqui P, Sanogo
YO, Caruso G, Raoult D. ‘‘Ehrlichia walkerii’’ a new
Ehrlichia detected in I. ricinus collected from asym-
ptomatic humans in northern Italy. In: Pertrovee &
Avsiec-Zupane, eds. International Conference on
Rickettsiae and Rickettsial Disease. Lubljana,
Slovenia, 2002.
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